Bright Minds Biosciences IncDRUG
Price$49.21

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Free Cash Flow -$1.4MTTM through 30 Sep 2024

Margins

Current

Returns

-8.9%ROE
-8.8%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio81.48x
Net Debt-$309.6Mnet cash position
Cash & Equivalents$5.7M

Quality Metrics

Piotroski F-Score2 / 9
Earnings-Beat Rate100.0%

Multi-Year Trend

Diluted EPS
'20'21'22'23'24
FY2024: $-0.65

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Pharmaceutical Research and Development$0
View details

Management is focused on advancing BMB-101 into late-stage clinical trials following positive Phase 2 BREAKTHROUGH study results.

Financials converted at 1.3527 from CAD.
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.